Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087776 · ClinicalTrials.gov registry record · Phase 3
Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
A Phase 3 study, sponsored by American Regent.
- Terminated
- Registry status
- Phase 3
- Development phase
- 393
- Enrollment target
NCT00087776 is a Phase 3 study that was terminated before completion, run by American Regent. The registered enrollment target is 393 participants.
The verdict
NCT00087776, a Phase 3 study, was terminated before completion, sponsored by American Regent.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 393 participants
- Enrollment target
Study Summary
The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine. In addition, the response rate to each drug, response duration, time to progression and time to treatment failure will be measured. Toxicity will be evaluated and compared between the two groups.
Interventions
- DRUG Dacarbazine
- DRUG Taxoprexin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 393 participants |
| Start Date | 2002-12-06 |
| Est. Completion | 2007-10-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087776
The ClinicalTrials.gov registry entry for NCT00087776 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 393 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dacarbazine is the first listed.
NCT00087776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087776 about?
NCT00087776 is a clinical study titled "Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma". The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine. In addition, the response rate to each drug, response duration, time to progression and time to treatment failure will be...
What is the current status of trial NCT00087776?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 393 participants. The study started on 2002-12-06. Estimated completion is 2007-10-27.
What interventions are being tested in trial NCT00087776?
The interventions under investigation include: Dacarbazine (DRUG), Taxoprexin (DRUG).
Who is sponsoring clinical trial NCT00087776?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.